• 14 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Original Article
    Cola rostrata K. Schum. constituents induce cytotoxicity through reactive oxygen species generation and mitochondrial membrane depolarisation
    Aim: While the traditional use of Cola rostrata in treating illnesses and diseases has not been reported, the presence of cytotoxic principles has been reported in phylogenetically and biogeograp [...] Read more.
    Babatunde E. Ajayi ... Amos A. Fatokun
    Published: December 28, 2023 Explor Target Antitumor Ther. 2023;4:1328–1344
    DOI: https://doi.org/10.37349/etat.2023.00200
    This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents
    View:660
    Download:13
    Times Cited: 0
    Open Access
    Review
    Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes
    Cholangiocarcinoma (CCA) is a highly aggressive type of adenocarcinoma distinguished by its invasiveness. Depending on specific anatomical positioning within the biliary tree, CCA can be categorized [...] Read more.
    Chaoqun Li ... Jieer Ying
    Published: December 28, 2023 Explor Target Antitumor Ther 2023;4:1310–1327
    DOI: https://doi.org/10.37349/etat.2023.00199
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    View:706
    Download:10
    Times Cited: 0
    Open Access
    Perspective
    Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?
    Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (P [...] Read more.
    Sabah Alaklabi ... Shipra Gandhi
    Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1301–1309
    DOI: https://doi.org/10.37349/etat.2023.00198
    This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer
    View:586
    Download:12
    Times Cited: 0
    Open Access
    Review
    Current implications and challenges of artificial intelligence technologies in therapeutic intervention of colorectal cancer
    Irrespective of men and women, colorectal cancer (CRC), is the third most common cancer in the population with more than 1.85 million cases annually. Fewer than 20% of patients only survive beyond f [...] Read more.
    Kriti Das ... Chakresh Kumar Jain
    Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1286–1300
    DOI: https://doi.org/10.37349/etat.2023.00197
    This article belongs to the special issue Artificial Intelligence for Precision Oncology
    Open Access
    Review
    Post-translational modulation of cell signalling through protein succinylation
    Cells need to adapt their activities to extra- and intracellular signalling cues. To translate a received extracellular signal, cells have specific receptors that transmit the signal to downstream p [...] Read more.
    Katharina F. Kubatzky ... Dayoung Yu
    Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1260–1285
    DOI: https://doi.org/10.37349/etat.2023.00196
    This article belongs to the special issue Posttranslational Modifications in Health and Disease
    View:1038
    Download:34
    Times Cited: 0
    Open Access
    Review
    Telehealth in breast cancer following the coronavirus disease 2019 pandemic
    Breast cancer (BC) is the second most diagnosed cancer in 2018 with around 2.3 million cases globally in 2020. In March 2020 and after its worldwide spread, the World Health Organization (WHO) decla [...] Read more.
    Jean Zeghondy ... Barbara Pistilli
    Published: December 26, 2023 Explor Target Antitumor Ther. 2023;4:1249–1259
    DOI: https://doi.org/10.37349/etat.2023.00195
    This article belongs to the special issue COVID-19 and Cancer
    View:489
    Download:10
    Times Cited: 0
    Open Access
    Review
    Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy
    A generalized therapeutic strategy for various disease conditions, including cancer, is to deplete or inactivate harmful protein targets. Various forms of protein or gene silencing molecules, e.g.,  [...] Read more.
    Mansi Joshi ... Abhijit De
    Published: December 26, 2023 Explor Target Antitumor Ther. 2023;4:1227–1248
    DOI: https://doi.org/10.37349/etat.2023.00194
    This article belongs to the special issue Posttranslational Modifications in Health and Disease
    View:947
    Download:40
    Times Cited: 0
    Open Access
    Original Article
    Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing tumour protein 53 gene status
    Aim: In response to DNA damage the serine/threonine-specific protein kinase checkpoint kinase 1 (CHK1) is activated allowing cells to enter S phase (S) and G2 phase (G2) cell-cycle arrest. CHK1 i [...] Read more.
    Ali JN Duabil ... George DD Jones
    Published: December 21, 2023 Explor Target Antitumor Ther. 2023;4:1210–1226
    DOI: https://doi.org/10.37349/etat.2023.00193
    View:727
    Download:17
    Times Cited: 0
    Open Access
    Original Article
    Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer
    Aim: It is important to identify anti-cancer compounds that can inhibit specific molecular targets to eradicate androgen-receptor negative (ARneg), androgen-independent (AI) prostate cancer, whic [...] Read more.
    Vignesh Sivaganesh, Bela Peethambaran
    Published: December 20, 2023 Explor Target Antitumor Ther. 2023;4:1188–1209
    DOI: https://doi.org/10.37349/etat.2023.00192
    This article belongs to the special issue Molecular Targeted Therapy for Cancer
    View:700
    Download:14
    Times Cited: 0
    Open Access
    Case Report
    Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
    Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate wit [...] Read more.
    Sviatoslav Chekhun ... Maria Saigí
    Published: December 13, 2023 Explor Target Antitumor Ther. 2023;4:1182–1187
    DOI: https://doi.org/10.37349/etat.2023.00191
    View:1036
    Download:15
    Times Cited: 0